Krijger GC, Ponsard B, Harfensteller M, Wolterbeek HT, Nijsen JWF. The necessity of nuclear reactors for targeted radionuclide therapies.
Trends Biotechnol 2013;
31:390-6. [PMID:
23731577 DOI:
10.1016/j.tibtech.2013.04.007]
[Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2013] [Revised: 04/24/2013] [Accepted: 04/24/2013] [Indexed: 11/28/2022]
Abstract
Nuclear medicine has been contributing towards personalized therapies. Nuclear reactors are required for the working horses of both diagnosis and treatment, i.e., Tc-99m and I-131. In fact, reactors will remain necessary to fulfill the demand for a variety of radionuclides and are essential in the expanding field of targeted radionuclide therapies for cancer. However, the main reactors involved in the global supply are ageing and expected to shut down before 2025. Therefore, the fields of (nuclear) medicine, nuclear industry and politics share a global responsibility, faced with the task to secure future access to suitable nuclear reactors. At the same time, alternative production routes should be industrialized. For this, a coordinating entity should be put into place.
Collapse